Biogen Inc. buy Royal Bank of Canada
Start price
13.02.25
/
50%
€130.50
Target price
13.02.26
€215.73
Performance (%)
-13.91%
Price
04.07.25
€112.35
Summary
This prediction is currently active. The prediction for Biogen Inc. disappoints with a performance of -13.91%. This prediction currently runs until 13.02.26. The prediction end date can be changed by Royal_Bank_of_Canada at any time. Royal_Bank_of_Canada has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Biogen Inc. | 4.318% | 4.318% |
| iShares Core DAX® | -1.315% | -2.266% |
| iShares Nasdaq 100 | 0.272% | 1.449% |
| iShares Nikkei 225® | -2.496% | 1.560% |
| iShares S&P 500 | 0.504% | 1.340% |
Comments by Royal_Bank_of_Canada for this prediction
In the thread Biogen Inc. diskutieren
Biogen Inc. (NASDAQ: BIIB) had its price target lowered by analysts at Royal Bank of Canada from $231.00 to $225.00. They now have an "outperform" rating on the stock.
Ratings data for BIIB provided by MarketBeat